Swedish Orphan Biovitrum AB (publ) (SOBI)
Free
No email, no account, no signup.
Pulling latest news for Swedish Orphan Biovitrum AB (publ)…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
HOLD
Sentiment
9/10
Risk
5/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has improved on the back of two regulatory approvals and an additional regulatory milestone via a partner (ViroGates), while takeover speculation continues to provide market support.
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Rare disease pharmaceuticals
Market Cap
$14.1B
Market sentiment
Sentiment has improved on the back of two regulatory approvals and an additional regulatory milestone via a partner (ViroGates), while takeover speculation continues to provide market support.
Why HOLD ?
The Q1 report is now out and was strong (revenue/EBITA beat and continued mix shift toward the strategic portfolio), reducing the need to stay in a "review" stance. However, the Arthrosi deal increases leverage and integration/execution risk, so the base call shifts to hold while monitoring leverage, margins and launch momentum into Q2.
- Hold; consider selectively adding on weakness if Q2 confirms continued CER growth and net debt/EBITDA stabilises or improves post-Arthrosi.
Recent News
- Since 2026-04-13, Sobi released Q1 2026 results (2026-04-28) with revenue of SEK 7,184m (+11% reported, +24% CER) and adjusted EBITA of SEK 2,751m (38.3% margin), while reiterating full-year guidance. On the same day, Sobi announced completion of the Arthrosi Therapeutics acquisition, which increased net debt (reported ~SEK 17.7bn; ~1.5x net debt/EBITDA). The company also communicated ESG/patient initiatives (Earth Day, Unite4Rare).
Bull case
- The **Q1 report (28 Apr)** could confirm continued strong sales and margins.
- Positive momentum after **upgraded outlook** and a strong 2025.
Unlock to read more →
Bear case
- **Integration and financing costs** from Arthrosi may weigh near term.
Unlock to read more →
Catalysts
16 Jul 2026 — Q2 2026 report (Jan–Jun)
Dilution Risk
Assessment: Low
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Swedish Orphan Biovitrum AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.